Sangamo Therapeutics (SGMO) Proxy Filing summary

Executive summary

• The annual meeting will be held virtually on June 12, 2025, to elect nine directors, approve executive compensation, amend the 2018 Equity Incentive Plan, and ratify the external auditor appointment.

• Stockholders of record as of April 17, 2025, are eligible to vote on these matters.

• The proxy statement details voting procedures, board structure, compensation, and governance practices.

Voting matters and shareholder proposals

• Four proposals: election of nine directors, advisory approval of executive compensation, amendment of the 2018 Equity Incentive Plan (adding 14M shares), and ratification of Ernst & Young LLP as auditor.

• Board recommends voting FOR all proposals.

• Shareholder proposals for the 2026 meeting must be submitted by December 31, 2025, for inclusion in proxy materials.

Board of directors and corporate governance

• Board consists of nine members, eight of whom are independent; CEO is the only non-independent director.

• Board diversity is emphasized, considering gender, age, tenure, and professional background.

• Board committees: Audit, Compensation, and Nominating & Corporate Governance, each with defined responsibilities and independent members.

• Chair of the Board is independent and separate from the CEO role.

• Directors attended at least 75% of meetings; eight of nine attended the 2024 annual meeting.